Literature DB >> 25752834

Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.

Kevin V Lemley1, Robert H Mak2.   

Abstract

A new trial provides further evidence that rituximab treatment can reduce the risk of relapse in children with steroid-dependent idiopathic nephrotic syndrome. Addition of a single infusion of rituximab to steroid therapy was associated with a decrease in proteinuria at 3 months and a significant increase in the relapse-free period.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25752834     DOI： 10.1038/nrneph.2015.26

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  8 in total

1.  Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Authors:  Alessia Fornoni; Junichiro Sageshima; Changli Wei; Sandra Merscher-Gomez; Robier Aguillon-Prada; Alexandra N Jauregui; Jing Li; Adela Mattiazzi; Gaetano Ciancio; Linda Chen; Gaston Zilleruelo; Carolyn Abitbol; Jayanthi Chandar; Wacheree Seeherunvong; Camillo Ricordi; Masami Ikehata; Maria Pia Rastaldi; Jochen Reiser; George W Burke
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Abatacept in B7-1-positive proteinuric kidney disease.

Authors:  Chih-Chuan Yu; Alessia Fornoni; Astrid Weins; Samy Hakroush; Dony Maiguel; Junichiro Sageshima; Linda Chen; Gaetano Ciancio; Mohd Hafeez Faridi; Daniel Behr; Kirk N Campbell; Jer-Ming Chang; Hung-Chun Chen; Jun Oh; Christian Faul; M Amin Arnaout; Paolo Fiorina; Vineet Gupta; Anna Greka; George W Burke; Peter Mundel
Journal:  N Engl J Med       Date:  2013-11-08       Impact factor: 91.245

3.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Authors:  Pietro Ravani; Alberto Magnasco; Alberto Edefonti; Luisa Murer; Rossella Rossi; Luciana Ghio; Elisa Benetti; Floriana Scozzola; Andrea Pasini; Nadia Dallera; Felice Sica; Mirco Belingheri; Francesco Scolari; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

Review 4.  The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient.

Authors:  Jai Radhakrishnan; Daniel C Cattran
Journal:  Kidney Int       Date:  2012-08-15       Impact factor: 10.612

5.  Should we consider MMF therapy after rituximab for nephrotic syndrome?

Authors:  Guido Filler; Shih-Han Susan Huang; Ajay P Sharma
Journal:  Pediatr Nephrol       Date:  2011-05-01       Impact factor: 3.714

6.  Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.

Authors:  Pietro Ravani; Roberta Rossi; Alice Bonanni; Robert R Quinn; Felice Sica; Monica Bodria; Andrea Pasini; Giovanni Montini; Alberto Edefonti; Mirco Belingheri; Donatella De Giovanni; Giancarlo Barbano; Ludovica Degl'Innocenti; Francesco Scolari; Luisa Murer; Jochen Reiser; Alessia Fornoni; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2015-01-15       Impact factor: 10.121

7.  Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.

Authors:  Kazumoto Iijima; Mayumi Sako; Kandai Nozu; Rintaro Mori; Nao Tuchida; Koichi Kamei; Kenichiro Miura; Kunihiko Aya; Koichi Nakanishi; Yoshiyuki Ohtomo; Shori Takahashi; Ryojiro Tanaka; Hiroshi Kaito; Hidefumi Nakamura; Kenji Ishikura; Shuichi Ito; Yasuo Ohashi
Journal:  Lancet       Date:  2014-06-22       Impact factor: 79.321

8.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

Authors:  Christian Faul; Mary Donnelly; Sandra Merscher-Gomez; Yoon Hee Chang; Stefan Franz; Jacqueline Delfgaauw; Jer-Ming Chang; Hoon Young Choi; Kirk N Campbell; Kwanghee Kim; Jochen Reiser; Peter Mundel
Journal:  Nat Med       Date:  2008-09       Impact factor: 53.440
  8 in total
  1 in total

1.  A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome.

Authors:  Mario Spatafora; Tommaso Bellini; Carmela Giordano; Gian Marco Ghiggeri
Journal:  BMJ Case Rep       Date:  2015-12-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.